Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Kryger, G., Silman, I., Sussman, J.L.(1999) Structure 7: 297-307
- PubMed: 10368299 
- DOI: https://doi.org/10.1016/s0969-2126(99)80040-9
- Primary Citation of Related Structures:  
1EVE - PubMed Abstract: 
Several cholinesterase inhibitors are either being utilized for symptomatic treatment of Alzheimer's disease or are in advanced clinical trials. E2020, marketed as Aricept, is a member of a large family of N-benzylpiperidine-based acetylcholinesterase (AChE) inhibitors developed, synthesized and evaluated by the Eisai Company in Japan. These inhibitors were designed on the basis of QSAR studies, prior to elucidation of the three-dimensional structure of Torpedo californica AChE (TcAChE). It significantly enhances performance in animal models of cholinergic hypofunction and has a high affinity for AChE, binding to both electric eel and mouse AChE in the nanomolar range.
Organizational Affiliation: 
Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel. Gitay.Kryger@Weizmann.ac.il